Health & Medicine Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health & Medicine Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Atherosclerosis
Patient enrollment completed in phase IIb CART-2 study with AGI-1067
September 1st, 2003
AtheroGenics, Inc., (AGIX) has recently completed enrollment in a phase IIb clinical trial evaluating its proprietary v-protectant drug candidate, AGI-1067, as a treatment for atherosclerosis and post-angioplasty restenosis. This clinical trial, referred to as CART-2, will evaluate the drug's effect on atherosclerosis as reflected by the change in plaque volume in coronary arteries. "This clinical trial will supply us with important anatomical data on the potential of AGI-1067 to reduce plaque in coronary blood vessels," said Russell M. Medford, MD, PhD, president and CEO for AtheroGenics. "If successful, this may provide us with enhanced label...
Source: Health & Medicine Week (2003-09-01)
|
